1. Introduction
===============

Adult-onset Still\'s disease (AOSD) is a systemic inflammatory disease characterized by spiking fever, skin rash, and arthritis.^\[[@R1]\]^ Although its pathogenesis is largely unknown,^\[[@R2]\]^ a growing number of studies support the hypothesis that dysregulation of inflammasome activation and the related overproduction of cytokines play a pivotal role in it, similar to other autoinflammatory diseases.^\[[@R3]\]^ Serum amyloid A (SAA) is an acute-phase reactant that is synthesized in the liver by inflammatory cytokines, the level of which can increase 1000-fold during inflammatory conditions.^\[[@R4]\]^ Within the SAA gene cluster, only the *SAA1* and *SAA2* genes encode acute-phase SAA.^\[[@R5]\]^ The presence of two single-nucleotide polymorphisms (SNPs) within exon 3 of the *SAA1* gene, 2995C/T and 3010C/T, define 3 haplotypes that correspond to *SAA1.1*, *SAA1.3*, and *SAA1.5*.^\[[@R6]\]^ Several studies have shown that the development of AA amyloidosis is positively related to the frequency of *SAA1.3* alleles in the Japanese population.^\[[@R7],[@R8]\]^ Subsequent investigations indicated that another SNP (rs12218) in the *SAA1* gene, at position -13 in the 5′ regulatory region of this gene, is in linkage disequilibrium with the *SAA1.3* allele and is closely associated with the occurrence of AA amyloidosis in Japanese and Caucasian rheumatoid arthritis patients.^\[[@R9],[@R10]\]^ Moreover, a functional study suggested that the T variant at this SNP is associated with greater transcriptional activity of the *SAA1* gene.^\[[@R11]\]^

G-protein-coupled formyl peptide receptor 2 (FPR2) is one of the receptors for SAA.^\[[@R12]\]^ In addition to FPR2, several receptors for SAA have been identified.^\[[@R13]\]^ Recent studies have suggested that SAA may play a role in the modulation of inflammation and immunity through these SAA receptors.^\[[@R14]\]^ In this study, we investigated the relationship between SAA1 gene polymorphism and AOSD.

2. Patients and methods
=======================

2.1. Design, setting, patients, and measurements
------------------------------------------------

We retrospectively evaluated 87 patients, who were diagnosed as AOSD and be treated at the Rheumatology Units of participating hospital group, between 2010 and 2017. The patients had all been diagnosed with AOSD according to the Yamaguchi criteria,^\[[@R15]\]^ after exclusion of infectious, hematologic, and inflammatory diseases. All patients had undergone laboratory tests, including a complete blood count, biochemistry, urinalysis, erythrocyte sedimentation rate (ESR) and ferritin. The demographic data of the enrolled patients, including clinical manifestations, treatments, prognosis, and complications, were collected using a standardized form. Each patient was assessed for the systemic score proposed by Pouchot et al^\[[@R26]\]^ for AOSD. This score assigns 1 point to each of 12 manifestations: fever, typical rash, pleuritis, pneumonia, pericarditis, hepatomegaly or abnormal liver function tests, splenomegaly, lymphadenopathy, leukocytosis \> 15,000/mm^3^, sore throat, myalgia, and abdominal pain (maximum score: 12 points). This study was approved by the institutional review board of the Sasebo City Hospital institutional review board (No. 2012-A-22) and participating hospitals. Two hundreds of healthy Japanese individuals without pre-existing medical diseases (90 men and 110 women 14 to 64 years, with a mean age of 38.6 ± 13.9 years) from East Japan (*n* = 86) and West Japan (*n* = 114) were enrolled in the study after obtaining informed consent.

2.2. Genotyping of *SAA1* gene
------------------------------

The *SAA1.1, 1.3*, and *1.5* alleles, corresponding to the *T-C, C-T*, and *C-C* haplotypes of the *C2995T* (rs1136743) and *C3010T* (rs1136747) polymorphisms were analyzed by the PCR-RFLP methods.^\[[@R8]\]^ The primers used for the PCR reaction were *5′-GCC AATTACATCGGCCTCAG-3′* (sense) and 5′-TGGCCA AAGAATCTCTGG AT-3′ (antisense). The 518-bp PCR products were digested with restriction enzyme BclI (Promega, San Luis Obispo, CA, USA) and BanI (Promega) and electrophoresed on a agarose gel. The genotypes of the *SAA1* -13C/T in the 5′-flanking region of the SAA1 gene, (rs12218) were also determined by the PCR--RFLP method.^\[[@R8]\]^ The primers used for PCR were *5′-ACATCT TGTTCCCTC AGGTTG-3′* (sense) and *5′-GCTGTAGCTGAGCTGCGG-3′* (antisense). The 229-bp PCR products were subjected to the restriction enzyme AciI (BioLabs, Beverly, MA, USA) and electrophoresed on a 12.5% polyacrylamide gel.

2.3. *MEFV* gene analysis
-------------------------

Peripheral blood samples (collected in vacutainers containing EDTA as anticoagulant) were used for genomic DNA isolation. Genomic DNA was isolated by the Promega Wizard Genomic DNA Purification Kit (Madison, WI, USA). Polymerase chain reaction (PCR) was performed using forward and reverse primers for each exon of the *MEFV* gene, as described previously.^\[[@R16]\]^ The polymerase chain reaction (PCR) products were purified and directly sequenced using ABI 3100 Genetic Analyzer (Applied Biosystems, Tokyo, Japan). The *MEFV* genetic analysis was approved by the Ethics Committee of Fukushima Medical University School of Medicine (2016, No. 2920).

2.4. Statistical analysis
-------------------------

Statistical analyses were out using SPSS version 17.0 (SPSS; Chicago, IL, USA). Hardy-Weinberg equilibrium was assessed by the chi-square test. Differences in the distribution of alleles between AOSD patients and control subjects were analyzed using the chi-square test. Differences among AOSD characteristics were analyzed by performing a Mann-Whitney\'s *U* test or Chi-squared test using 2 × 2 contingency tables.

3. Results
==========

3.1. Demographic findings of enrolled AOSD patients
---------------------------------------------------

A total of 87 Japanese patients (18 men and 69 women) who fulfilled the Yamaguchi criteria for AOSD^\[[@R15]\]^ were recruited into this study. All patients were ethnic Japanese. Routine blood tests including tests of C-reactive protein, serum ferritin, and liver enzymes were performed. The clinical manifestations of the enrolled patients are shown in Table [1](#T1){ref-type="table"}. Among the 87 enrolled patients with AOSD, 69 (79.3%) were women and the mean age at diagnosis was 49.3 ± 19.9 years old. Among these 87 patients, 51 patients (58.6%) were treated with immunosppressants (Cyclosporin A 38, Tacrolimus 4, Methotrexate 9).

###### 

Demographic findings of enrolled AOSD patients.
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3.2. *SAA1* gene haplotypes in Japanese patients with AOSD
----------------------------------------------------------

A segment of the *SAA1* gene with polymorphic sites was subjected to PCR restriction fragment length polymorphism (PCR-RFLP) analysis. Table [2](#T2){ref-type="table"} shows the frequencies of individuals with various genotypes and alleles at the *SAA1* locus in either AOSD patients (*n* = 87) or healthy Japanese subjects (*n* = 200). The frequency of the *SAA1.3* allele was increased in AOSD patients compared with that in healthy subjects (43.1% versus 37.5%), but the difference was not significant.

###### 

*SAA1* genotype and allele frequency in the AOSD patients and controls.
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3.3. Association of *SAA1* −13T allele with AOSD in Japanese
------------------------------------------------------------

The -13C/T polymorphism, in the 5′-flanking region of the SAA1 gene, which is in linkage disequilibrium with the *SAA1.3* allele, has been shown to be associated with susceptibility to AA amyloidosis in Japanese RA patients. We thus analyzed the -13C/T polymorphisms in AOSD patients and healthy Japanese subjects. The observed genotype frequencies did not differ from the expected frequencies of the genotypes under the assumption of Hardy--Weinberg equilibrium (data not shown). Allele frequencies of -13C/T differed between the 2 groups (Table [3](#T3){ref-type="table"}), with the −13T allele being significantly more common in AOSD patients than in healthy subjects (50.6% versus 41.0%, *P* = .0336). This suggests that the −13T allele is associated with susceptibility to AOSD in the Japanese population. To evaluate the potential correlations of -13C/T alleles with the clinical manifestations of AOSD, we stratified the AOSD patients according to the presence of the −13T allele (Table [4](#T4){ref-type="table"}). AOSD patients with this allele were found to have been treated more frequently (64.7% versus 36.8%, *P* = .029) with immunosuppressants (Cyclosporin A 33, Tacrolimus 2, Methotrexate 9), but there was no significant difference in the other clinical manifestations. We also compared the systemic score according to the genotypes of SAA -13C/T among AOSD patients. As demonstrated in Figure [1](#F1){ref-type="fig"}, we could not find a significant difference in systemic score according to the genotype SAA -13C/T allele in Japanese patients with AOSD.

###### 

Genotype and allele frequencies of −13 C/T *SAA1* in AOSD patients and the healthy subjects.
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###### 

Demographic and clinical features of AOSD patients with or without -13 T allele.
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![Systemic scores of AOSD patients among the different genotypes of *SAA1*-13C/T allele. The values of the systemic scores of each AOSD patients stratified by the genotypes of *SAA1*-13C/T allele are shown. Values are expressed as mean ± standard deviation. NS; not significant. AOSD = adult onset Still\'s disease.](medi-97-e13394-g005){#F1}

3.4. *MEFV* variant analysis
----------------------------

All AOSD patients were successfully genotyped for the *MEFV* gene. *MEFV* variants were identified in 46 AOSD patients (57.6%), the distribution of which is shown in Table [5](#T5){ref-type="table"}. We stratified the AOSD patients according to the presence or absence of *MEFV* variants, and then compared the clinical features between these groups (Table [6](#T6){ref-type="table"}). Although there was no statistically significant difference, AOSD patients with *MEFV* variants were more frequently associated with macrophage activation syndrome (34.7% versus 18.4%, *P* = .092) and the initial doses of prednisolone were higher compared with those without *MEFV* variants (35.9 ± 12.8 mg/day versus 31.8 ± 11.2 mg/day, *P* = .081). We also compared the frequencies of -13C/T polymorphisms between the AOSD patients stratified according to the presence of *MEFV* variants, but no significant differences were found (Table [7](#T7){ref-type="table"}).

###### 

*MEFV* genotypes of AOSD patients.
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###### 

Demographic and clinical features of AOSD patients with or without *MEFV* variants.
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###### 

Frequencies at -13C/T alleles in AOSD patients with or without *MEFV* variants.
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4. Discussion
=============

A major acute-phase reactant, SAA, is produced when the immune system senses potential danger signals including trauma, infection, and severe stress.^\[[@R17]\]^ Previous studies accumulated substantial evidence that SAA is involved in inflammatory disorders including autoinflammatory diseases.^\[[@R18]\]^ SAA has proinflammatory activities, including those involving cell migration and phagocytosis.^\[[@R19]\]^ It is also considered to be a danger signal that activates inflammasomes.^\[[@R20]\]^ Specifically, SAA is capable of activating NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome and subsequent IL-1β production,^\[[@R21]\]^ which play important roles in the pathogenesis of AOSD. Therefore, it is possible that SAA is important in the pathogenesis of autoinflammatory diseases including AOSD. Evidence has also been presented that the risk of AOSD is influenced by polymorphisms in proinflammatory genes including cytokines and components of the innate immune system.^\[[@R22]\]^ In this study, we found that polymorphisms of the *SAA1* gene were associated with the susceptibility to AOSD in the Japanese population. We demonstrated that the frequency of the T allele at position −13 in the *SAA1* gene (rs12218) was significantly increased in AOSD patients compared with that in healthy subjects. Previous studies also demonstrated the strong linkage disequilibrium between the *SAA1.3* allele and the *SAA1* −13T allele in the Japanese population.^\[[@R9]\]^ Our data also indicate that the allele frequency of *SAA1.3* was increased in AOSD patients compared with that in healthy controls, although this did not reach statistical significance.

The overproduction of IL-1β is responsible for a variety of autoinflammatory disorders, including AOSD.^\[[@R23]\]^ Recent studies have shown that SAA activates the NLRP3 inflammasome and subsequent IL-1β production in innate immune cells,^\[[@R24]\]^ suggesting a link between SAA and autoinflammatory diseases. SNPs identified in the promoter region of the *SAA1* gene have been shown to be associated with a predisposition to AA amyloidosis.^\[[@R8],[@R9]\]^ The mechanisms by which *SAA1* gene polymorphism (-13C/T, rs12218) may be associated with AOSD are unknown. Moriguchi et al demonstrated that a C/T switch at -13 of SAA1 gene (-13C/T) is associated with increased transcription activity of this gene correlating susceptibility to AA amyloidosis in Japanese patients with rheumatoid arthritis. They found 4 major haplotypes of SAA1 promoter based on 3 SNPs at -61, -13, and -2 of the SAA1 promoter region and designed them -14C~1~ (C-C-G), -13C~2~ (G-C-G), -13C~3~ (G-C-A), and -13T (C-T-G). They demonstrated that −13T promoter exhibited greater transcriptional activity compared to other cis-regulating elements promoter haplotypes -13C~1~, -13C~2~, and -13C~3~ in luciferase reporter gene assays under IL-1β or IL-6 stimulation. The serum concentration of A-SAA to C-reactive protein (CRP) were significantly higher in subjects carrying SAA1.5 allele than in those carrying1.3 allele. The data from luciferase reporter assay seem inconsistent with these laboratory data. However, an increased transcriptional ability of A-SAA does not necessarily result in a serum SAA concentrations due to other factors, such as A-SAA stability and degradation may influence the serum concentrations of A-SAA.

It has been reported that *SAA1* polymorphisms are associated with the risk of inflammatory disorders.^\[[@R5]\]^ The TT genotype is associated with an increased risk for carotid artery intima-media thickness in obese individuals.^\[[@R25]\]^ Interestingly, AOSD patients with the −13T allele in this study were found to have been treated with immunosuppressants more frequently than those without this allele. These findings suggest that the T allele may confer more proinflammatory phenotypes, including cytokine production, in AOSD patients. In comparison, the CC genotype of vs12218 was found to be more common among patients suffering from coronary artery disease.^\[[@R26]\]^ Because of the presence of multiple receptors, the effects of SAA are pleiotropic and may not be categorized simply as being proinflammatory.

We previously reported that individuals carrying the T allele of -13C/T (rs12218) have increased susceptibility to familial Mediterranean fever (FMF), a hereditary autoinflammatory disease.^\[[@R27]\]^ The significance of the difference in the T-allele frequency compared with that in controls is greater in FMF than in AOSD, a nonhereditary autoimmune disease. We could not provide a plausible explanation for this. We aimed to determine whether any SNPs within the *SAA1* gene conferred an increased risk of susceptibility to AOSD. However, collection of AOSD would require collaboration with multiple centers and there is the possibility that the numbers of patients involved would still be small. We assumed that there is a shared genetic basis for AOSD; however, the clinical phenotype of AOSD is heterogeneous.^\[[@R3]\]^ This complexity may have contributed to the less significant association between *SAA1* gene polymorphisms and AOSD, compared with that for FMF, a more categorized autoinflammatory disorder.

*MEFV* gene mutations/polymorphisms have been implicated in more than 1 genetic autoinflammatory disease, FMF.^\[[@R28]\]^ Therefore, we considered that it would be reasonable for the *MEFV* gene to also be associated with AOSD. The allele frequencies of common polymorphisms in exons 2 and 3 of the MEFV gene in AOSD patients (R408Q, 3.3%; P369S, 3.3%; E148Q, 23.7%) were similar to those of healthy Japanese subjects, as described previously.^\[[@R29]\]^ Therefore, *MEFV* gene polymorphisms may not be involved in the susceptibility to AOSD. However, these genetic variations may be related to the clinical manifestations of AOSD. Although no statistically significant results were obtained, AOSD patients carrying *MEVF* variants showed a tendency to be associated with MAS and to be treated with higher doses of steroids than those without these variants. These findings suggest that variation in autoinflammatory genes may modify the disease phenotype of AOSD.

Our study has some limitations, one of which was the relatively small number of studied subjects. This case--control study for *SAA1* gene polymorphisms may have been underpowered due to the rarity of patients with AOSD. Another limitation of this study is that the examined subjects were ethnically Japanese; hence, caution should be exercised when extrapolating our results to other ethnic groups. In the present study, we did not examine the differences in circulating SAA levels between each genotype, which was a limitation of our study.

5. Conclusions
==============

In conclusion, we suggest that the SNPs in the promoter region of SAA1 gene (-13C/T) may correlate with AOSD in the Japanese population. Further studies are necessary to determine, which are the predominant SNPs with the susceptibility to AOSD in various ethnic population.

Author contributions
====================

**Conceptualization:** Atshushi Kawakami.

**Data curation:** Tomoyuki Asano, Shuzo Sato, Hiroko Kobayashi, Hiroshi Watanabe, Eiji Suzuki, Tadashi Nakamura, Toshimasa Shimizu, Masataka Umeda, and Fumiaki Nonaka.

**Formal analysis:** Kiyoshi Migita, Tomoyuki Asano, and Tomohiro Koga.

**Investigation:** Kiyoshi Migita, Hiroshi Furukawa, and Tomohiro Koga.

**Methodology:** Hiroshi Furukawa and Tomohiro Koga.

**Project administration:** Kiyoshi Migita, Tomohiro Koga, Yukitaka Ueki, Katsumi Eguchi, and Atshushi Kawakami.

**Supervision:** Yukitaka Ueki, Katsumi Eguchi, and Atshushi Kawakami.

**Validation:** Tomohiro Koga.

**Writing -- original draft:** Makiko Yashiro.

**Writing -- review, and editing:** Kiyoshi Migita and Hiroshi Furukawa.

Abbreviations: AOSD = adult onset Still\'s disease, PCR-RFLP = PCR restriction fragment length polymorphism, SAA = serum amyloid A, SNPs = single-nucleotide polymorphisms.

Ethical approval for this study (No. 21003) was provided by the Ethics Committee of Nagasaki Medical Center and written informed consent was obtained from each individual.

The study was supported by the Practical Research Project for Rare / Intractable Diseases from Japan Agency for Medical Research and Development, AMED.

The authors have no conflicts of interest to disclose.
